A Phase 2 interventional study of Chlorhexidine 2.5 mg and Placebo chip in Peri-implantitis, sponsored by Dexcel Pharma Technologies Ltd.. Completed at 2 sites in Israel. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-06-15.
Sponsored by Dexcel Pharma Technologies Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to assess the efficacy and the safety of Chlorhexidine Gluconate chip (Periochip®) versus Placebo Chip in treatment of symptoms in patients with Peri-Implantitis.
This is a Phase 2a study assessing the safety and efficacy of Chlorhexidine Gluconate chip (Periochip®) versus Placebo Chip in treatment of symptoms in patients with Peri-Implantitis
323 studies on the registry are indexed under Peri-Implantitis; 88 are open to participants now.
This study's enrollment of 60 is above the median of 40 across 195 interventional studies indexed under Peri-Implantitis.
Browse Peri-Implantitis studies →Dexcel Pharma Technologies Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PerioChip®, consisting of 2.5 mg Chlorhexidine Gluconate PerioChips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
Drug: Chlorhexidine 2.5 mg
Placebo Chip Placebo Chips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
Drug: Placebo chip
Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket
Pocket depth is the measurement of the distance from the coronal edge of the gingival margin to the base of the pocket. Measurements were taken with a standard 15-mm University of North Carolina (UNC) periodontal probe. Change from baseline in PPD was calculated as Week 24 PPD minus Baseline PPD such that a negative difference indicates an improvement in condition
Time frame: Baseline to Week 24
Clinical Attachment Levels (CAL)
Loss of attachment is defined as the distance in millimetres that the base of the pocket has migrated apically from the gingival margin of the crown. CAL was calculated at the same site that PPD was measured
Time frame: Baseline to Week 24
Bleeding on Probing (BOP)
BOP was measured at the same site after measuring the PPD. The scoring system used for recording the BOP was a dichotomous one: 0 = No bleeding 1 = Bleeding on probing of the pocket base
Time frame: Baseline to Week 24
| Milestone | Chlorhexidine Chip (Periochip®) | Placebo Chip |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 26 |
| Not completed | 0 | 4 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Protocol violation | 0 | 2 |
Pocket depth is the measurement of the distance from the coronal edge of the gingival margin to the base of the pocket. Measurements were taken with a standard 15-mm University of North Carolina (UNC) periodontal probe. Change from baseline in PPD was calculated as Week 24 PPD minus Baseline PPD such that a negative difference indicates an improvement in condition
| mm | Chlorhexidine Chip (Periochip®) | Placebo Chip |
|---|---|---|
| Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket | -2.13 ± 1.399 | -1.79 ± 1.149 |
Loss of attachment is defined as the distance in millimetres that the base of the pocket has migrated apically from the gingival margin of the crown. CAL was calculated at the same site that PPD was measured
| mm | Chlorhexidine Chip (Periochip®) | Placebo Chip |
|---|---|---|
| Clinical Attachment Levels (CAL) | -2.18 ± 1.394 | -1.76 ± 1.257 |
BOP was measured at the same site after measuring the PPD. The scoring system used for recording the BOP was a dichotomous one: 0 = No bleeding 1 = Bleeding on probing of the pocket base
| Target implant | Chlorhexidine Chip (Periochip®) | Placebo Chip |
|---|---|---|
| Bleeding on Probing (BOP) | 23 | 16 |
Collected over Baseline through Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chlorhexidine Chip (Periochip®) | 0/30 (0%) | 0/30 (0%) | 15/30 (50%) |
| Placebo Chip | 0/30 (0%) | 2/30 (6.7%) | 16/30 (53.3%) |
| Event | Chlorhexidine Chip (Periochip®) | Placebo Chip |
|---|---|---|
| Head injuryInjury, poisoning and procedural complications | 0/30 | 1/30 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/30 | 1/30 |
| Event | Chlorhexidine Chip (Periochip®) | Placebo Chip |
|---|---|---|
| Implant site painGeneral disorders | 2/30 | 4/30 |
| Gingival swellingGastrointestinal disorders | 3/30 | 0/30 |
| Periodontal diseaseGastrointestinal disorders | 3/30 | 0/30 |
| Periodontal inflammationGastrointestinal disorders | 0/30 | 3/30 |
| Feeling coldGeneral disorders | 3/30 | 1/30 |
| Aphthous ulcerGastrointestinal disorders | 1/30 | 2/30 |
| ToothacheGastrointestinal disorders | 0/30 | 2/30 |
| NasopharyngitisInfections and infestations | 2/30 | 0/30 |
| Dental restoration failureInjury, poisoning and procedural complications | 0/30 | 2/30 |
| Tooth extractionSurgical and medical procedures | 1/30 | 2/30 |
| Age, Continuous(years) | Chlorhexidine Chip (Periochip®) | Placebo Chip | Total |
|---|---|---|---|
| Mean | 56.7 ± 10.51 | 60.1 ± 7.88 | 58.4 ± 9.38 |
| Sex: Female, Male(Participants) | Chlorhexidine Chip (Periochip®) | Placebo Chip | Total |
|---|---|---|---|
| Female | 20 | 15 | 35 |
| Male | 10 | 15 | 25 |
| Race (NIH/OMB)(Participants) | Chlorhexidine Chip (Periochip®) | Placebo Chip | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 30 | 30 | 60 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Chlorhexidine Chip (Periochip®) | Placebo Chip | Total |
|---|---|---|---|
| Israel | 30 | 30 | 60 |
The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2021, 9 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chlorhexidine
Dexcel Pharma Technologies Ltd.